Amelly Kok, Associate
Amelly is a corporate solicitor specialising in corporate finance advisory and transactional work for public and private companies.
AboutAmelly is a corporate solicitor specialising in corporate finance advisory and transactional work for public and private companies. Her experience includes mergers and acquisitions, private equity and compliance matters.
Amelly is admitted to practise in England and Wales, and is also qualified to practise in Malaysia.
- Advising companies on their admission to trading on AIM including MayAir Group plc, Harvest Minerals Limited, Circle Property plc and Aquatic Foods Group plc (acting for the nominated adviser), and advising listed companies and nominated advisers on fundraising exercises by way of placings, open offers and offers for subscription
- Assisting on a range of transactions in the corporate team including corporate M&A, corporate reorganisations, private equity, shareholder arrangements and joint ventures
- Providing advice, planning and preparation for AGMs and annual report compliance, and general corporate governance issues for listed, AIM traded and other public and private companies
- Providing general corporate advice to public and private companies on a variety of company law and compliance matters
News & Insights
Charles Russell Speechlys advises Kreos Capital VI (UK) Ltd on growth capital investment in retail monitoring solution BeMyEye
Charles Russell Speechlys has advised Kreos Capital VI (UK) Limited on its €3 million growth capital investment in BeMyEye Holdings Limited.
Charles Russell Speechlys advises Taptica International Ltd on recommended all-share acquisition of AIM listed RhythmOne
Taptica is an AIM listed global advertising technologies platform provider.
Charles Russell Speechlys advises on two Capital Markets deals announced in two days
The team advised Transense Technologies Plc, and joint brokers WH Ireland, Canaccord Genuity and First Energy Capital.
Charles Russell Speechlys advises Kreos and SVB on £20m growth capital investment to Mereo BioPharma
We advised Kreos Capital and Silicon Valley Bank on the refinancing of £20 million growth capital investment to Mereo BioPharma Group